ID   LIMK1_HUMAN             Reviewed;         647 AA.
AC   P53667; B7Z6I8; D3DXF4; D3DXF5; O15283; Q15820; Q15821; Q75MU3;
AC   Q9Y5Q1;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 3.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=LIM domain kinase 1;
DE            Short=LIMK-1;
DE            EC=2.7.11.1;
GN   Name=LIMK1; Synonyms=LIMK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8183554;
RA   Mizuno K., Okano I., Ohashi K., Nunoue K., Kuma K., Miyata T.,
RA   Nakamura T.;
RT   "Identification of a human cDNA encoding a novel protein kinase with
RT   two repeats of the LIM/double zinc finger motif.";
RL   Oncogene 9:1605-1612(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   TYR-580.
RC   TISSUE=Hippocampus, and Placenta;
RX   PubMed=8689688; DOI=10.1016/S0092-8674(00)80077-X;
RA   Frangiskakis J.M., Ewart A.K., Morris C.A., Mervis C.B., Bertrand J.,
RA   Robinson B.F., Klein B.P., Ensing G.J., Everett L.A., Green E.D.,
RA   Proeschel C., Gutowski N.J., Noble M., Atkinson D.L., Odelberg S.J.,
RA   Keating M.T.;
RT   "LIM-kinase1 hemizygosity implicated in impaired visuospatial
RT   constructive cognition.";
RL   Cell 86:59-69(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT TYR-580, AND GENE DELETION
RP   IN WILLIAMS-BEUREN SYNDROME.
RX   PubMed=8812460; DOI=10.1006/geno.1996.0469;
RA   Osborne L.R., Martindale D.W., Scherer S.W., Shi X.-M., Huizenga J.,
RA   Heng H.H.Q., Costa T., Pober B., Lew L., Brinkman J., Rommens J.,
RA   Koop B.F., Tsui L.-C.;
RT   "Identification of genes from a 500-kb region at 7q11.23 that is
RT   commonly deleted in Williams syndrome patients.";
RL   Genomics 36:328-336(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SELF-ASSOCIATION,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-84; 177-GLY-LEU-178;
RP   ASP-460; 496-ARG--ARG-506; 503-ARG--GLY-505 AND THR-508.
RC   TISSUE=Epidermal carcinoma;
RX   PubMed=10196227; DOI=10.1074/jbc.274.16.11352;
RA   Edwards D.C., Gill G.N.;
RT   "Structural features of LIM kinase that control effects on the actin
RT   cytoskeleton.";
RL   J. Biol. Chem. 274:11352-11361(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PHOSPHORYLATION AT THR-508 BY PAK1.
RX   PubMed=10559936; DOI=10.1038/12963;
RA   Edwards D.C., Sanders L.C., Bokoch G.M., Gill G.N.;
RT   "Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling
RT   to actin cytoskeletal dynamics.";
RL   Nat. Cell Biol. 1:253-259(1999).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH ROCK1.
RX   PubMed=10436159; DOI=10.1126/science.285.5429.895;
RA   Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A.,
RA   Obinata T., Ohashi K., Mizuno K., Narumiya S.;
RT   "Signaling from Rho to the actin cytoskeleton through protein kinases
RT   ROCK and LIM-kinase.";
RL   Science 285:895-898(1999).
RN   [10]
RP   PHOSPHORYLATION AT THR-508, MUTAGENESIS OF THR-508, AND INTERACTION
RP   WITH ROCK1.
RX   PubMed=10652353; DOI=10.1074/jbc.275.5.3577;
RA   Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K.;
RT   "Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation
RT   at threonine 508 within the activation loop.";
RL   J. Biol. Chem. 275:3577-3582(2000).
RN   [11]
RP   PHOSPHORYLATION BY CDC42BP.
RX   PubMed=11340065; DOI=10.1074/jbc.C100196200;
RA   Sumi T., Matsumoto K., Shibuya A., Nakamura T.;
RT   "Activation of LIM kinases by myotonic dystrophy kinase-related Cdc42-
RT   binding kinase alpha.";
RL   J. Biol. Chem. 276:23092-23096(2001).
RN   [12]
RP   PHOSPHORYLATION BY PAK4.
RX   PubMed=11413130; DOI=10.1074/jbc.M100871200;
RA   Dan C., Kelly A., Bernard O., Minden A.;
RT   "Cytoskeletal changes regulated by the PAK4 serine/threonine kinase
RT   are mediated by LIM kinase 1 and cofilin.";
RL   J. Biol. Chem. 276:32115-32121(2001).
RN   [13]
RP   FUNCTION.
RX   PubMed=11832213; DOI=10.1016/S0092-8674(01)00638-9;
RA   Niwa R., Nagata-Ohashi K., Takeichi M., Mizuno K., Uemura T.;
RT   "Control of actin reorganization by Slingshot, a family of
RT   phosphatases that dephosphorylate ADF/cofilin.";
RL   Cell 108:233-246(2002).
RN   [14]
RP   FUNCTION.
RX   PubMed=12807904; DOI=10.1074/jbc.M305802200;
RA   Kaji N., Ohashi K., Shuin M., Niwa R., Uemura T., Mizuno K.;
RT   "Cell cycle-associated changes in Slingshot phosphatase activity and
RT   roles in cytokinesis in animal cells.";
RL   J. Biol. Chem. 278:33450-33455(2003).
RN   [15]
RP   INTERACTION WITH CDKN1C.
RX   PubMed=14530263; DOI=10.1074/jbc.M309334200;
RA   Yokoo T., Toyoshima H., Miura M., Wang Y., Iida K.T., Suzuki H.,
RA   Sone H., Shimano H., Gotoda T., Nishimori S., Tanaka K., Yamada N.;
RT   "p57Kip2 regulates actin dynamics by binding and translocating LIM-
RT   kinase 1 to the nucleus.";
RL   J. Biol. Chem. 278:52919-52923(2003).
RN   [16]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [17]
RP   FUNCTION, INTERACTION WITH SSH1, PHOSPHORYLATION AT THR-508, AND
RP   DEPHOSPHORYLATION.
RX   PubMed=15660133; DOI=10.1038/sj.emboj.7600543;
RA   Soosairajah J., Maiti S., Wiggan O., Sarmiere P., Moussi N.,
RA   Sarcevic B., Sampath R., Bamburg J.R., Bernard O.;
RT   "Interplay between components of a novel LIM kinase-slingshot
RT   phosphatase complex regulates cofilin.";
RL   EMBO J. 24:473-486(2005).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16230460; DOI=10.1083/jcb.200504029;
RA   Nishita M., Tomizawa C., Yamamoto M., Horita Y., Ohashi K., Mizuno K.;
RT   "Spatial and temporal regulation of cofilin activity by LIM kinase and
RT   Slingshot is critical for directional cell migration.";
RL   J. Cell Biol. 171:349-359(2005).
RN   [19]
RP   PHOSPHORYLATION AT SER-323 BY MAPKAPK2.
RX   PubMed=16456544; DOI=10.1038/sj.emboj.7600973;
RA   Kobayashi M., Nishita M., Mishima T., Ohashi K., Mizuno K.;
RT   "MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced
RT   actin remodeling and cell migration.";
RL   EMBO J. 25:713-726(2006).
RN   [20]
RP   INTERACTION WITH HSP90AA1.
RX   PubMed=16641196; DOI=10.1096/fj.05-5258fje;
RA   Li R., Soosairajah J., Harari D., Citri A., Price J., Ng H.L.,
RA   Morton C.J., Parker M.W., Yarden Y., Bernard O.;
RT   "Hsp90 increases LIM kinase activity by promoting its homo-
RT   dimerization.";
RL   FASEB J. 20:1218-1220(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF TPPP.
RX   PubMed=18028908; DOI=10.1016/j.yexcr.2007.08.012;
RA   Acevedo K., Li R., Soo P., Suryadinata R., Sarcevic B., Valova V.A.,
RA   Graham M.E., Robinson P.J., Bernard O.;
RT   "The phosphorylation of p25/TPPP by LIM kinase 1 inhibits its ability
RT   to assemble microtubules.";
RL   Exp. Cell Res. 313:4091-4106(2007).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=17188549; DOI=10.1016/j.biocel.2006.11.011;
RA   Bernard O.;
RT   "Lim kinases, regulators of actin dynamics.";
RL   Int. J. Biochem. Cell Biol. 39:1071-1076(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210; THR-229; SER-310
RP   AND SER-337, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307 AND SER-310, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210; THR-229; SER-302
RP   AND SER-310, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   REVIEW ON FUNCTION.
RX   PubMed=22886629; DOI=10.1002/med.20230;
RA   Manetti F.;
RT   "LIM kinases are attractive targets with many macromolecular partners
RT   and only a few small molecule regulators.";
RL   Med. Res. Rev. 32:968-998(2012).
RN   [28]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21682918; DOI=10.1186/1476-4598-10-75;
RA   McConnell B.V., Koto K., Gutierrez-Hartmann A.;
RT   "Nuclear and cytoplasmic LIMK1 enhances human breast cancer
RT   progression.";
RL   Mol. Cancer 10:75-75(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298 AND SER-310, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-508.
RX   PubMed=23633677; DOI=10.1126/scisignal.2003627;
RA   Borroni E.M., Cancellieri C., Vacchini A., Benureau Y., Lagane B.,
RA   Bachelerie F., Arenzana-Seisdedos F., Mizuno K., Mantovani A.,
RA   Bonecchi R., Locati M.;
RT   "Beta-arrestin-dependent activation of the cofilin pathway is required
RT   for the scavenging activity of the atypical chemokine receptor D6.";
RL   Sci. Signal. 6:RA30-RA30(2013).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-190; ASN-247 AND GLN-422.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 330-637.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the human limk1 kinase domain in complex with
RT   staurosporine.";
RL   Submitted (JUL-2011) to the PDB data bank.
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays an essential
CC       role in the regulation of actin filament dynamics. Acts downstream
CC       of several Rho family GTPase signal transduction pathways.
CC       Activated by upstream kinases including ROCK1, PAK1 and PAK4,
CC       which phosphorylate LIMK1 on a threonine residue located in its
CC       activation loop. LIMK1 subsequently phosphorylates and inactivates
CC       the actin binding/depolymerizing factors cofilin-1/CFL1, cofilin-
CC       2/CFL2 and destrin/DSTN, thereby preventing the cleavage of
CC       filamentous actin (F-actin), and stabilizing the actin
CC       cytoskeleton. In this way LIMK1 regulates several actin-dependent
CC       biological processes including cell motility, cell cycle
CC       progression, and differentiation. Phosphorylates TPPP on serine
CC       residues, thereby promoting microtubule disassembly. Stimulates
CC       axonal outgrowth and may be involved in brain development. Isoform
CC       3 has a dominant negative effect on actin cytoskeletal changes.
CC       Required for atypical chemokine receptor ACKR2-induced
CC       phosphorylation of cofilin (CFL1). {ECO:0000269|PubMed:10196227,
CC       ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:11832213,
CC       ECO:0000269|PubMed:12807904, ECO:0000269|PubMed:15660133,
CC       ECO:0000269|PubMed:16230460, ECO:0000269|PubMed:18028908,
CC       ECO:0000269|PubMed:23633677}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts (via LIM domain) with the cytoplasmic domain of
CC       NRG1 (By similarity). Interacts with NISCH (By similarity).
CC       Interacts with RLIM and RNF6 (By similarity). Self-associates to
CC       form homodimers. Interacts with HSP90AA1; this interaction
CC       promotes LIMK1 dimerization and subsequent transphosphorylation.
CC       Interacts with CDN1C. Interacts with SSH1. Interacts with ROCK1.
CC       {ECO:0000250, ECO:0000269|PubMed:10436159,
CC       ECO:0000269|PubMed:10652353, ECO:0000269|PubMed:14530263,
CC       ECO:0000269|PubMed:15660133, ECO:0000269|PubMed:16641196}.
CC   -!- INTERACTION:
CC       P29066:Arrb1 (xeno); NbExp=2; IntAct=EBI-444403, EBI-4303019;
CC       P29067:Arrb2 (xeno); NbExp=2; IntAct=EBI-444403, EBI-1636616;
CC       P23528:CFL1; NbExp=2; IntAct=EBI-444403, EBI-352733;
CC       O95835:LATS1; NbExp=5; IntAct=EBI-444403, EBI-444209;
CC       P50281:MMP14; NbExp=4; IntAct=EBI-444403, EBI-992788;
CC       Q13153:PAK1; NbExp=5; IntAct=EBI-444403, EBI-1307;
CC       Q13177:PAK2; NbExp=2; IntAct=EBI-444403, EBI-1045887;
CC       P63319:Prkcg (xeno); NbExp=3; IntAct=EBI-444403, EBI-12598030;
CC       Q8WYL5:SSH1; NbExp=7; IntAct=EBI-444403, EBI-1222387;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Predominantly found
CC       in the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P53667-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P53667-2; Sequence=VSP_003125;
CC       Name=3;
CC         IsoId=P53667-3; Sequence=VSP_003126, VSP_003127;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=4;
CC         IsoId=P53667-4; Sequence=VSP_043331;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highest expression in both adult and fetal
CC       nervous system. Detected ubiquitously throughout the different
CC       regions of adult brain, with highest levels in the cerebral
CC       cortex. Expressed to a lesser extent in heart and skeletal muscle.
CC   -!- PTM: Autophosphorylated (By similarity). Phosphorylated on Thr-508
CC       by ROCK1 and PAK1, resulting in activation. Phosphorylated by PAK4
CC       which increases the ability of LIMK1 to phosphorylate cofilin.
CC       Phosphorylated at Ser-323 by MAPKAPK2 during activation of VEGFA-
CC       induced signaling, which results in activation of LIMK1 and
CC       promotion of actin reorganization, cell migration, and tubule
CC       formation of endothelial cells. Dephosphorylated and inactivated
CC       by SSH1. Phosphorylated by CDC42BP. {ECO:0000250,
CC       ECO:0000269|PubMed:10559936, ECO:0000269|PubMed:10652353,
CC       ECO:0000269|PubMed:11340065, ECO:0000269|PubMed:11413130,
CC       ECO:0000269|PubMed:15660133, ECO:0000269|PubMed:16456544,
CC       ECO:0000269|PubMed:23633677}.
CC   -!- PTM: Ubiquitinated. 'Lys-48'-linked polyubiquitination by RNF6
CC       leads to proteasomal degradation through the 26S proteasome,
CC       modulating LIMK1 levels in the growth cone and its effect on
CC       axonal outgrowth. Also polyubiquitinated by RLIM (By similarity).
CC       {ECO:0000250}.
CC   -!- DISEASE: Note=LIMK1 is located in the Williams-Beuren syndrome
CC       (WBS) critical region. WBS results from a hemizygous deletion of
CC       several genes on chromosome 7q11.23, thought to arise as a
CC       consequence of unequal crossing over between highly homologous
CC       low-copy repeat sequences flanking the deleted region.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LIMK1ID41159ch7q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D26309; BAA05371.1; -; mRNA.
DR   EMBL; U62293; AAB17545.1; -; Genomic_DNA.
DR   EMBL; U62293; AAB17546.1; -; Genomic_DNA.
DR   EMBL; U63721; AAC13885.1; -; Genomic_DNA.
DR   EMBL; U63721; AAC13886.1; -; Genomic_DNA.
DR   EMBL; AF134379; AAD25742.1; -; mRNA.
DR   EMBL; AK300382; BAH13274.1; -; mRNA.
DR   EMBL; AC005056; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005057; AAS07438.1; -; Genomic_DNA.
DR   EMBL; CH471200; EAW69620.1; -; Genomic_DNA.
DR   EMBL; CH471200; EAW69621.1; -; Genomic_DNA.
DR   EMBL; CH471200; EAW69622.1; -; Genomic_DNA.
DR   EMBL; CH471200; EAW69623.1; -; Genomic_DNA.
DR   CCDS; CCDS5563.1; -. [P53667-1]
DR   CCDS; CCDS56491.1; -. [P53667-4]
DR   PIR; JP0078; JP0078.
DR   RefSeq; NP_001191355.1; NM_001204426.1. [P53667-4]
DR   RefSeq; NP_002305.1; NM_002314.3. [P53667-1]
DR   UniGene; Hs.647035; -.
DR   PDB; 3S95; X-ray; 1.65 A; A/B=330-637.
DR   PDB; 5HVJ; X-ray; 2.20 A; A/B=329-638.
DR   PDB; 5HVK; X-ray; 3.50 A; A/C=329-638.
DR   PDB; 5L6W; X-ray; 2.53 A; L=330-637.
DR   PDBsum; 3S95; -.
DR   PDBsum; 5HVJ; -.
DR   PDBsum; 5HVK; -.
DR   PDBsum; 5L6W; -.
DR   ProteinModelPortal; P53667; -.
DR   SMR; P53667; -.
DR   BioGrid; 110172; 40.
DR   DIP; DIP-31605N; -.
DR   IntAct; P53667; 37.
DR   MINT; MINT-2833166; -.
DR   STRING; 9606.ENSP00000336740; -.
DR   BindingDB; P53667; -.
DR   ChEMBL; CHEMBL3836; -.
DR   DrugBank; DB08912; Dabrafenib.
DR   GuidetoPHARMACOLOGY; 2054; -.
DR   iPTMnet; P53667; -.
DR   PhosphoSitePlus; P53667; -.
DR   SwissPalm; P53667; -.
DR   BioMuta; LIMK1; -.
DR   DMDM; 90185240; -.
DR   EPD; P53667; -.
DR   MaxQB; P53667; -.
DR   PaxDb; P53667; -.
DR   PeptideAtlas; P53667; -.
DR   PRIDE; P53667; -.
DR   DNASU; 3984; -.
DR   Ensembl; ENST00000336180; ENSP00000336740; ENSG00000106683. [P53667-1]
DR   Ensembl; ENST00000435201; ENSP00000414606; ENSG00000106683. [P53667-3]
DR   Ensembl; ENST00000538333; ENSP00000444452; ENSG00000106683. [P53667-4]
DR   GeneID; 3984; -.
DR   KEGG; hsa:3984; -.
DR   UCSC; uc003uaa.3; human. [P53667-1]
DR   CTD; 3984; -.
DR   DisGeNET; 3984; -.
DR   GeneCards; LIMK1; -.
DR   HGNC; HGNC:6613; LIMK1.
DR   HPA; HPA028064; -.
DR   HPA; HPA028516; -.
DR   MalaCards; LIMK1; -.
DR   MIM; 601329; gene.
DR   neXtProt; NX_P53667; -.
DR   OpenTargets; ENSG00000106683; -.
DR   Orphanet; 904; Williams syndrome.
DR   PharmGKB; PA30386; -.
DR   eggNOG; ENOG410IEZ9; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00530000063025; -.
DR   HOGENOM; HOG000013121; -.
DR   HOVERGEN; HBG052328; -.
DR   InParanoid; P53667; -.
DR   KO; K05743; -.
DR   PhylomeDB; P53667; -.
DR   TreeFam; TF318014; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   SignaLink; P53667; -.
DR   SIGNOR; P53667; -.
DR   ChiTaRS; LIMK1; human.
DR   EvolutionaryTrace; P53667; -.
DR   GeneWiki; LIMK1; -.
DR   GenomeRNAi; 3984; -.
DR   PRO; PR:P53667; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106683; -.
DR   CleanEx; HS_LIMK1; -.
DR   ExpressionAtlas; P53667; baseline and differential.
DR   Genevisible; P53667; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; ISS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031072; F:heat shock protein binding; IDA:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; NAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004871; F:signal transducer activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0051444; P:negative regulation of ubiquitin-protein transferase activity; IDA:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0032233; P:positive regulation of actin filament bundle assembly; IDA:BHF-UCL.
DR   GO; GO:0045773; P:positive regulation of axon extension; ISS:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0007266; P:Rho protein signal transduction; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR001781; Znf_LIM.
DR   Pfam; PF00412; LIM; 2.
DR   Pfam; PF00595; PDZ; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00132; LIM; 2.
DR   SMART; SM00228; PDZ; 1.
DR   SUPFAM; SSF50156; SSF50156; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00478; LIM_DOMAIN_1; 2.
DR   PROSITE; PS50023; LIM_DOMAIN_2; 2.
DR   PROSITE; PS50106; PDZ; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Kinase; LIM domain; Metal-binding; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation;
KW   Williams-Beuren syndrome; Zinc.
FT   CHAIN         1    647       LIM domain kinase 1.
FT                                /FTId=PRO_0000075803.
FT   DOMAIN       25     75       LIM zinc-binding 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00125}.
FT   DOMAIN       84    137       LIM zinc-binding 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00125}.
FT   DOMAIN      165    258       PDZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN      339    604       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     345    353       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    460    460       {ECO:0000250}.
FT   BINDING     368    368       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     210    210       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     229    229       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     298    298       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     302    302       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     307    307       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     310    310       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     323    323       Phosphoserine; by MAPKAPK2.
FT                                {ECO:0000269|PubMed:16456544}.
FT   MOD_RES     337    337       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     508    508       Phosphothreonine; by ROCK1 and PAK1.
FT                                {ECO:0000269|PubMed:10559936,
FT                                ECO:0000269|PubMed:10652353,
FT                                ECO:0000269|PubMed:15660133,
FT                                ECO:0000269|PubMed:23633677}.
FT   VAR_SEQ       1     51       MRLTLLCCTWREERMGEEGSELPVCASCGQRIYDGQYLQAL
FT                                NADWHADCFR -> MLLASAPRRRRFLQRAK (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043331.
FT   VAR_SEQ       1     14       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_003125.
FT   VAR_SEQ     294    305       LRSCSIDRSPGA -> FARTWVALSPSA (in isoform
FT                                3). {ECO:0000303|PubMed:10196227}.
FT                                /FTId=VSP_003126.
FT   VAR_SEQ     306    647       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10196227}.
FT                                /FTId=VSP_003127.
FT   VARIANT     190    190       G -> A (in dbSNP:rs35827364).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042246.
FT   VARIANT     247    247       S -> N (in dbSNP:rs55661242).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042247.
FT   VARIANT     422    422       R -> Q (in dbSNP:rs55679316).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042248.
FT   VARIANT     580    580       F -> Y (in dbSNP:rs178412).
FT                                {ECO:0000269|PubMed:8689688,
FT                                ECO:0000269|PubMed:8812460}.
FT                                /FTId=VAR_050148.
FT   MUTAGEN      84     84       C->S: Enhances actin aggregation.
FT                                {ECO:0000269|PubMed:10196227}.
FT   MUTAGEN     177    178       GL->EA: Enhances actin aggregation.
FT                                {ECO:0000269|PubMed:10196227}.
FT   MUTAGEN     460    460       D->N: Abrogates kinase activity.
FT                                {ECO:0000269|PubMed:10196227}.
FT   MUTAGEN     496    506       Missing: Reduces actin aggregation.
FT                                {ECO:0000269|PubMed:10196227}.
FT   MUTAGEN     503    505       RKK->GAA: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:10196227}.
FT   MUTAGEN     508    508       T->A: Abolishes activation by ROCK1.
FT                                {ECO:0000269|PubMed:10196227,
FT                                ECO:0000269|PubMed:10652353}.
FT   MUTAGEN     508    508       T->EE: Enhances kinase activity.
FT                                {ECO:0000269|PubMed:10196227,
FT                                ECO:0000269|PubMed:10652353}.
FT   MUTAGEN     508    508       T->V,E: Reduces kinase activity.
FT                                {ECO:0000269|PubMed:10196227,
FT                                ECO:0000269|PubMed:10652353}.
FT   STRAND      332    334       {ECO:0000244|PDB:3S95}.
FT   HELIX       336    338       {ECO:0000244|PDB:3S95}.
FT   STRAND      339    346       {ECO:0000244|PDB:3S95}.
FT   STRAND      349    358       {ECO:0000244|PDB:3S95}.
FT   TURN        359    361       {ECO:0000244|PDB:3S95}.
FT   STRAND      364    371       {ECO:0000244|PDB:3S95}.
FT   HELIX       375    388       {ECO:0000244|PDB:3S95}.
FT   STRAND      399    405       {ECO:0000244|PDB:3S95}.
FT   STRAND      408    414       {ECO:0000244|PDB:3S95}.
FT   HELIX       421    427       {ECO:0000244|PDB:3S95}.
FT   HELIX       434    453       {ECO:0000244|PDB:3S95}.
FT   STRAND      465    468       {ECO:0000244|PDB:3S95}.
FT   STRAND      474    476       {ECO:0000244|PDB:3S95}.
FT   HELIX       513    515       {ECO:0000244|PDB:3S95}.
FT   HELIX       518    521       {ECO:0000244|PDB:3S95}.
FT   HELIX       529    544       {ECO:0000244|PDB:3S95}.
FT   TURN        550    552       {ECO:0000244|PDB:3S95}.
FT   STRAND      559    561       {ECO:0000244|PDB:3S95}.
FT   HELIX       563    569       {ECO:0000244|PDB:3S95}.
FT   HELIX       579    586       {ECO:0000244|PDB:3S95}.
FT   HELIX       591    593       {ECO:0000244|PDB:3S95}.
FT   HELIX       597    613       {ECO:0000244|PDB:3S95}.
FT   HELIX       618    634       {ECO:0000244|PDB:3S95}.
SQ   SEQUENCE   647 AA;  72585 MW;  9838BEFBE7006447 CRC64;
     MRLTLLCCTW REERMGEEGS ELPVCASCGQ RIYDGQYLQA LNADWHADCF RCCDCSASLS
     HQYYEKDGQL FCKKDYWARY GESCHGCSEQ ITKGLVMVAG ELKYHPECFI CLTCGTFIGD
     GDTYTLVEHS KLYCGHCYYQ TVVTPVIEQI LPDSPGSHLP HTVTLVSIPA SSHGKRGLSV
     SIDPPHGPPG CGTEHSHTVR VQGVDPGCMS PDVKNSIHVG DRILEINGTP IRNVPLDEID
     LLIQETSRLL QLTLEHDPHD TLGHGLGPET SPLSSPAYTP SGEAGSSARQ KPVLRSCSID
     RSPGAGSLGS PASQRKDLGR SESLRVVCRP HRIFRPSDLI HGEVLGKGCF GQAIKVTHRE
     TGEVMVMKEL IRFDEETQRT FLKEVKVMRC LEHPNVLKFI GVLYKDKRLN FITEYIKGGT
     LRGIIKSMDS QYPWSQRVSF AKDIASGMAY LHSMNIIHRD LNSHNCLVRE NKNVVVADFG
     LARLMVDEKT QPEGLRSLKK PDRKKRYTVV GNPYWMAPEM INGRSYDEKV DVFSFGIVLC
     EIIGRVNADP DYLPRTMDFG LNVRGFLDRY CPPNCPPSFF PITVRCCDLD PEKRPSFVKL
     EHWLETLRMH LAGHLPLGPQ LEQLDRGFWE TYRRGESGLP AHPEVPD
//
